Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer
2008

RUNX3 Gene and Pancreatic Cancer

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): Nomoto S, Kinoshita T, Mori T, Kato K, Sugimoto H, Kanazumi N, Takeda S, Nakao A

Primary Institution: University of Nagoya

Hypothesis

RUNX3 gene alterations may play a role in the carcinogenesis of pancreatic cancer.

Conclusion

RUNX3 is frequently methylated in primary pancreatic cancer tissues, and its inactivation is associated with worse survival outcomes.

Supporting Evidence

  • Hypermethylation was detected in 62.5% of pancreatic cancer tissues.
  • Loss of heterozygosity was found in 34.3% of cases.
  • Hypermethylation of RUNX3 was significantly correlated with worse prognosis.

Takeaway

This study found that a gene called RUNX3, which helps prevent cancer, is often turned off in pancreatic cancer, making the disease worse.

Methodology

The study examined the methylation status of the RUNX3 promoter, loss of heterozygosity at 1p36, and conducted mutation analysis in 32 pancreatic cancer tissues.

Limitations

The study may have been limited by the presence of normal cell contamination in tumor samples.

Participant Demographics

Patients with pancreatic cancer from Nagoya University Hospital.

Statistical Information

P-Value

0.0143

Statistical Significance

p=0.0143

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604333

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication